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EDITORIAL REVIEW
Hepatitis B infection and renal disease: Clinical,
immunopathogenetic and therapeutic considerations
Following the Nobel prize-winning discovery of the hepatitis
B surface antigen (HBsAg) by Blumberg, Alter and Visnich in
1964 [1], it became apparent that hepatitis B viral (HBV)
infection is widespread in man, chronically infecting over 5% of
the world population, and is a major cause of acute and chronic
hepatitis, cirrhosis, and hepatocellular carcinoma [2]. As many
as 150 to 200 million people have persistent carriage of HBsAg
in their circulation, with the majority of these HBsAg "carri-
ers" residing in the Orient, Oceania, and sub-Saharan Africa
[3].
During the last 20 years a variety of immunologically medi-
ated disorders have also been associated with HBV infection
(Table 1). The major immune disorders consist of a serum
sickness-like syndrome that is observed with acute HBV infec-
tion [4, 5], and vasculitis [6] and membranous and membrano-
proliferative glomerulonephritis (GN) [7, 8] that are more
commonly associated with chronic HBV infection. In this
review we will examine the association of HBV infection with
these major syndromes, as well as their salient features, and
distinguishing clinical characteristics. A re-evaluation of the
immunopathogenesis of these immune disorders, as well as
considerations regarding immunosuppressive therapy in the
management of these syndromes will also be presented.
HBV associated antigens
The HBV virus is a complex DNA virus that can exist in the
circulation in several forms. The complete virion (that is, the
"Dane" particle) is a 42 nm particle with an outer surface
envelope (HBsAg) and an inner nucleocapsid core containing
the hepatitis B core antigen (HBcAg), DNA polymerase, pro-
tein kinase activity, and circular double-stranded DNA with a
variable single-stranded segment (Fig. 1) [reviewed in 9]. In
addition, "incomplete" 22 nm spherical and filamentous viral
particles consisting solely of HBsAg are usually the dominant
viral product in the circulation and in acute infection may exist
in concentrations of 1012 to 1014 particles/mi serum [10].
The major antigens of the HBV virus are shown in Table 2. At
least four major subtypes of HBsAg have been identified, which
are all structurally similar and consist of a common group a
determinant and one of a pair of the d/y and w/r subgroups [9].
Analysis of HBsAg demonstrates that it contains multiple
copies of three protein subunits: the "major" protein consisting
of a non-glycosylated (P24) or glycosylated (GP27) form, the
"middle" protein consisting of two forms (GP33, GP36) with
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different degrees of glycosylation, and the "large" polypeptide,
also present in two forms (P39, GP42) [91. The "middle" and
"large" polypeptides are structurally related to the "major"
polypeptide, but have an extension of their amino terminal [15]
that provides additional epitopes. None of these antigens cir-
culate freely, but rather only in association with the 22 and 42
nm particles.
The HBcAg is an anionic DNA binding protein with a
molecular wt of 8.5 to 9 x 106 daltons [12] and consists of
multiple copies of a 22,000 molecular wt polypeptide (P22) [9].
It is not found free in the circulation [16], but can be released
from complete virions by detergent treatment [12]. Structurally
similar to the HBcAg is the hepatitis B e antigen (HBeAg)
(molecular wt 15,000 [9]), which can be released from the
HBcAg by proteolytic treatment or sodium dodecyl sulfate [17].
Unlike the HBcAg, HBeAg may be found in the circulation
either as a dimer (molecular wt 30,000), coupled to albumin
(molecular wt 90,000), or as a hexamer bound to 1, 2, or 3
anti-HBe IgG antibodies (molecular wt 240,000, 400,000 or
540,000, respectively) [13]. The presence of HBeAg in the
circulation, whether small ("free") or large (that is, bound to
anti-HBe antibody), correlates with the presence within the
serum of complete viral particles and general infectivity of the
individual [10]. Although two subtypes of HBeAg can be
recognized by immunodiffusion or radioimmunoassay [13], they
appear to consist of similar polypeptide composition with the
difference in antigenicity of HBeAg/2 being due to a conforma-
tional change resulting from the polymerization of the HBeAg
[18].
Several other HBV associated antigens exist. DNA polymer-
ase, a basic protein with a molecular wt of 90,000 [9], is present
within the core of the complete HBV particle but is not present
as a free antigen in the circulation, although antipolymerase
antibodies may occasionally be detected [16, 19]. The X open
reading frame of the HBV genome encodes for the 17,000
molecular wt X protein [14], the function of which remains
unknown but which appears to be expressed late in HBV
infection following integration of the HBV DNA into the host
genome [14]. Its presence as detected by anti-X antibodies has
primarily been found in patients with cirrhosis or hepatocellular
carcinoma [14], and no association of the X protein with
vasculitis and/or GN has been reported. Finally, superinfection
of the chronic "carrier" state may occur with the 1.7 kilobase
RNA delta virus (HDV) which requires the presence of HBsAG
for survival [20]. Its major product, the delta antigen, has only
rarely been found in the circulation, and infection is usually
detected by measuring 1gM and IgG anti-HDV antibodies [20].
No association of delta infection with the extrahepatic manifes-
tations of HBV has to our knowledge been reported.
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Table 1. Extrahepatic immunological syndromes associated with
hepatitis B infection
Serum sickness—vasculitis syndromes
Acute serum sickness-like syndrome
Polyarteritis nodosa
Venulitis/palpable purpura
Henoch-Schönlein purpura'
Essential mixed cryoglobulinemia'
Glomerulonephritis
Membranous
Membranoproliferative
Mesangial proliferative
IgA nephropathy'
Diffuse proliferative'
Systemic lupus erythematosus'
Minimal change disease'
'Controversial
HBsAg
HBcAg
HBeA0
Fig. I. Schematic of HB V virus (adapted with permission from Cooper
BW and Klimek JJ. The pathogenesis and prevention of hepatitis B
infection. Infections in Surgery 6:639, 1987).
HBV serum sickness-like syndrome
Clinical presentation
A serum sickness-like syndrome may occur in 10 to 25% of
patients in the early prodrome of acute HBV hepatitis. Fever, a
maculopapular or urticarial rash, and transient arthralgias and/
or arthritis involving distal and large joints of the extremities are
common [4, 5, 21—23]. In only rare cases has transient protein-
uria [23], microscopic hematuria [22] (including RBC casts (4])
and sterile pyuria [22] been observed, and to our knowledge no
renal histology has been reported. The syndrome lasts 3 to 10
days, responds readily to salicylates, and often resolves prior to
the onset of jaundice [21, 22]. Occasionally arthritis and palpa-
ble purpura occur in patients with chronic active HBV hepatitis
[22, 24, 25], in which case the rash is characterized by penvas-
cular neutrophil infiltration, as opposed to the urticarial/macu-
lopapular rashes occurring prior to acute hepatitis in which the
infiltration in the small blood vessels is mainly lymphocytic
[25].
HBV associated polyarteritis nodosa (HBV-PAN)
Association
Although PAN was first described by Kussmaul and Maier in
1866 [26], an association of PAN with hepatitis was not recog-
nized until over 80 years later when Paull reported four army
officers who developed acute hepatitis and PAN after receiving
a yellow fever vaccine [27]. In 1970 two separate reports further
linked the association of PAN with hepatitis B [6, 28], and in
Table 2. HBV associated antigens
Antigen Gene Molecular wt p1 Reference
HBsAg
HBcAg
HBeAg
DNA pol
X protein
S
C
C
P
X
3.7—4.6 x 10
8.5—9 x l0"
3 X l0—5.4 X I0
9 x i0
1.7 X l0"
3.9-4.9
3.7—4.0
4.3—8.4
"basic"
unknown
[ll]
[121
(131
(91
[141
a Properties of adw and ayw subtypes of HBsAgb Molecular wt of liver derived HBcAg
C Molecular wt of synthesized X protein polypeptide component
Table 3. Incidence of HEsAg in classic PAN
Country Rate (%) Reference Year
United States
New York 6/16 (38%) 29 1971
Ann Arbor 1/16 (6%) 30 1975
Ann Arbor 4/17 (24%) 31 1987
Rochester (Mayo) 3/27 (11%) 32 1980
Bethesda (NIH) 6/17 (35%) 33 1979
England (Bristol) 2/25 (8%) 34 1982
Ireland (Dublin) 0/9 (0%) 35 1987
France
Paris 3/17 (18%) 36 1983
Lyons 30/55 (54%) 37 1974
Switzerland 3/10 (30%) 38 1986
various series the presence of HBsAg in the serum has been
noted in 0 to 54% of cases of PAN (Table 3) [29—38]. Of interest
is the observation that HBV-PAN has been primarily reported
in Europe and the United States where the prevalence of the
HBsAg carrier state is greatest in adults, and infection is usually
acquired via a parenteral route [10]. In contrast, in the Orient
and Africa, where HBV-PAN appears to be less common, HBV
infection most often occurs in childhood via transmission from
parents or siblings [10]. Furthermore, the variability in inci-
dence of HBsAg in PAN within the United States may be
partially explained by the underlying prevalence of intravenous
drug abuse and the HBV carrier rate at the various reporting
centers. Thus, in New York, USA, up to 40% of PAN is HBV
associated as opposed to Ann Arbor and Rochester, Minnesota,
USA, where the rates are from 6 to 25% (Table 3).
Clinical presentation
HBV-PAN usually presents weeks to several months follow-
ing a clinically mild acute hepatitis [39-421, but may rarely
predate clinical hepatitis or occur several years after chronic
active hepatitis has developed [431. Most cases have been
reported in adults [22, 29, 32, 33, 431, but a case has been
described in an 8-month-old infant [441.
The initial presentation is similar to the serum sickness-like
syndrome and includes fever, arthralgias and/or arthritis, ur-
ticaria, and palpable purpura [6, 29, 43]. Unlike the prodromal
serum sickness syndrome which resolves spontaneously, in
HBV-PAN a frank vasculitis develops over several weeks and
may involve virtually any organ. Abdominal pain secondary to
mesenteric isehemia, mononeuritis multiplex secondary to in-
volvement of the vasa nervorum of peripheral nerves, and
myocardial ischemia from coronary artery involvement may all
result [22, 43]. Pulmonary involvement resulting in the Churg-
Single-stranded DNA
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Strauss syndrome (defined as the presence of asthma, eosino-
philia, and granulomatous and eosinophilic vasculitis) is rare
with chronic HBV infection but has been reported [36]. Renal
involvement may present as renin-dependent hypertension,
microscopic hematuria, non-nephrotic or nephrotic proteinuria,
or even renal failure [22, 40, 43, 45].
Laboratory tests typically reveal mildly-elevated liver func-
tion tests (especially transaminases) [6, 29, 43]. HBsAg and
anti-HBc are usually present in the circulation [37]. Occasion-
ally both HBsAg and anti-HBs are present in the serum [37, 46],
and then the anti-HBs may be directed against a different
subtype of HBsAg than that which is present [46]. It is possible
that with more sensitive assays (such as, radioimmunoassay)
that the frequency of co-occurrence of anti-HBs and HBsAg
could increase [47].
The pathology in HBV-PAN consists of focal inflammation of
the small and medium sized arteries, often at sites of branching
148,49]. The inflammation is panmural, often at different stages,
and is characterized by fibrinoid necrosis, leukocyte infiltration,
fibrin deposition, and occasional aneurysm formation [49].
Rarely involvement of the post-capillary venules occurs, in
which case the patients present with palpable purpura and a
clinical picture resembling Henoch-Schönlein purpura [39, 50].
Liver pathology usually demonstrates either chronic active or
chronic persistent [22, 43, 49] hepatitis, and rarely acute hepa-
titis [6, 22].
The renal pathology in HBV-PAN may be limited to medium
sized arteries with only ischemic changes in glomeruli (that is,
"classic" PAN) [51]. However, various forms of GN have been
reported, including diffuse proliferative [22, 40, 48], membran-
oproliferative (MPGN) [22, 48], mesangial proliferative [48],
and membranous (MGN) [22]. Segmental necrotizing GN asso-
ciated with crescent formation (that is, "microscopic" PAN),
although frequent in idiopathic PAN, is not associated with the
HBsAg carrier state [52—54] except for very rare cases [48, 55].
Idiopathic rapidly progressive GN is also only rarely associated
with HBV infection [56].
Distinguishing clinical characteristics
HBV-PAN is difficult to distinguish clinically from other
types of PAN. Non-HBV associated PAN may be associated
with prior administration of horse serum [57], sulfonamide
therapy [57], or methamphetamine use [43]. Serous otitis is
often associated with non-HBV PAN [43]. HBV-PAN is more
frequently associated with abnormal liver function tests [22, 43]
and aneurysm formation [31] than non-HBV PAN. HBV-PAN
also has a tendency to resolve over several months, whereas
non-HBV PAN may have a relapsing course [43]. Immunolog-
ical measurements including the level of serum complement [431
and/or the presence of circulating immune complexes (CICs),
however, are unable to separate these entities [29, 36].
Diagnosis of PAN can be made by skeletal muscle, peripheral
nerve, kidney or even testicular biopsy [34]. Angiography to
look for saccular or fusiform aneurysms and/or abnormal nar-
rowing of blood vessels is also useful and may be particularly of
value in HBV-PAN [31]. Renal angiography has the highest
diagnostic yield followed by examination of the celiac system
[31].
Pat ho genesis of the serum sickness and vasculitis syndromes
Most evidence suggests that the HBV serum sickness and
vasculitis syndromes result from passive deposition of HBV
antigen containing CICs in the vasculature and synovium,
followed by complement activation and leukocyte infiltration
[58]. The theory is based on the clinical and immunological
similarities of the HBV syndromes to acute and chronic serum
sickness due to foreign antigens in animals and man [57, 59—63].
As with the HBV serum sickness-like syndrome, acute serum
sickness in man is associated with minimal renal manifestations
such as mild proteinuria [59], and acute serum sickness in
rabbits is associated with a transient proliferative GN [60].
HBV-PAN is clinically similar to the vasculitis that can be
induced in rabbits [61, 62] and man [57] with repeated injections
of foreign antigens, particularly if administered to presensitized
individuals. Although an animal model of HBV-PAN does not
exist, both vasculitis and immune complex GN develop in
marmosets following intravenous infection with hepatitis A
virus [64].
In HBV serum sickness and vasculitis HBsAg probably
serves as the foreign antigen. CICs containing HBsAg and
anti-HBs antibodies have been detected in most patients with
HBV related serum sickness [23, 65] and PAN [6, 29, 39, 66].
Studies in which CICs have not been detected (using hemag-
glutination, hemagglutination inhibition, and ultracentnfuga-
tion) [67] may relate to the sensitivity of the assay [37]. For
example, in idiopathic PAN the Raji cell assay may correlate
better with disease activity as compared to the fluid phase Clq
binding assay [36]. Indeed, the presence of CICs as measured
by Raji cell assay [68] or by the demonstration of aggregation or
"clumping" of HBsAg particles by electron microscopy (EM)
[37] has been correlated with disease activity in HBV-PAN.
Also of interest is the observation that the infusion of anti-HBs
serum into two HBsAg carriers resulted in microscopic hema-
tuna and transient proteinuria, respectively [69]. Systemic
complement activation with depressed C3, C4 and total hemo-
lytic complement has also been observed in many but not all
patients with HBV serum sickness [4, 5, 22—24] and HBV-PAN
[6, 22, 29]. Finally, clearance of HBsAg from the blood of
patients with HBV-PAN, which has only been rarely observed,
has been associated with dramatic clinical remission [37].
The observation that the majority of patients with acute HBV
infection have CICs [70] yet extrahepatic manifestations are
present in the minority suggests that the content and other
characteristics of the CICs may be critical to their pathogenic-
ity. For example, Wands et al examined the contents of CICs in
patients with acute hepatitis B with and without arthritis [65].
Although both groups had CICs containing HBsAg, IgG, and
1gM, only patients with arthritis had CICs which also contained
complement components (C3, C4, CS) and IgA [65]. CICs from
patients with HBV-PAN may also be distinguished from CICs
from patients with HBV venulitis on the basis of their dissocia-
bility in acid pH (which may reflect antigen-antibody avidity)
and relative content of HBsAg [39].
Evidence for a role for HBsAg in HBV serum sickness is
further provided by studies in which HBsAg has been localized
in synovial vessel endothelium by immunofluorescence (IF) and
EM [24], or has been found in synovial fluid [4, 22]. HBsAg [6,
23, 25, 29, 45, 48—51, 66, 71, 72], IgG [41, 48, 49, 71, 72], and
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Table 4. Incidence of HBsAg antigenemia in children with
membranous GN according to the underlying prevalence of LIB sAg in
the reporting region
Country Rate (%) Year Reference
A. General population carrier rate 0.1—1.0%
USA (20%) 1985 80
Western Europe
France 14/33 (42%) 1979 81
Italy 9/14 (64%) 1985 82
B. General population carrier rate 1—5%
Eastern Europe
Poland 21/23 (91%) 1980 83
Poland 34/37 (92%) 1984 84
C. General population carrier rate 2—20%
Orient
Japan 16/28 (57%) 1985 85
Japan 13/16 (81%) 1987 86
South Korea 8/10 (80%) 1982 87
Hong Kong 15/16 (94%) 1982 88
Hong Kong 5/5 (100%) 1985 89
Taiwan 13/13 (100%) 1983 90
Africa
Zimbabwe 8/8 (100%) 1984 91
South Africa 25/28 (89%) 1983 92
1gM and C3 [6, 23, 25, 29, 41, 48—50, 71, 72] have also been
identified by IF and HBV viral particles by EM [50, 71] in blood
vessels of patients with HBY-vasculitis. Immune deposits con-
taimng HBsAg have also been demonstrated in glomeruli in
patients with HBV-PAN [48, 49]. The observation that 1gM is
more commonly localized than IgG at blood vessel sites and
that HBV-PAN often occurs during the early convalescence of
acute hepatitis [39—42] suggests that 1gM rather than IgG
immune complexes may be more likely pathogenic in HBV
vasculitis. Although 1gM antibodies have generally not been
mediators of tissue injury in serum sickness models, a prece-
dent for 1gM in mediating vascular disease has been the
demonstration of an 1gM autoantibody in the sera of patients
with Kawasaki's disease that binds interferon-stimulated hu-
man umbilical vein endothelial cells [73].
Although not all studies have been able to demonstrate
HBsAg and antibody at sites of vascular injury, it is possible
that the immune complexes may be rapidly cleared. In the
Arthus reaction antigen [74], antibody, and C3 [75] are removed
within 24 to 48 hours from the vessel wall, perhaps via a
neutrophil-dependent process [74]. Studies in man also confirm
that in cutaneous leukocytoclastic vasculitis IgG, 1gM, and C3
can be demonstrated by IF and immune deposits by EM only
when the rash is biopsied within 24 hours of presentation 176].
It has been argued that the localization of HBsAg and
antibodies in inflammatory sites may not reflect pathogenic
immune complex deposition, but rather may represent second-
ary trapping of immune reactants in damaged vasculature. The
demonstration of HBsAg in glomeruli and capillaries in renal
infarcts [51] or in focally sclerosed regions in glomeruli [77] and
the inability to demonstrate anti-HBs activity in tissue eluates
containing HBsAg and IgG [48] is consistent with this interpre-
tation. However, in this latter study the deposition of the
HBsAg did occur in areas of fresh injury, was absent in scarred
regions, and HBsAg was elutable only with antibody-antigen
dissociating buffers [48]. Furthermore, in one study neither
albumin or alpha-2-macroglobulin co-localized with HBsAg in
Table 5. Incidence of HBsAg antigenemia in adults with
membranous GN
General
carrier
Country Rate (%) rate Year Reference
Great Britain 1/28 (4%) <1% 1981 93
Scotland 0/54 (0%) <1% 1986 94
Hungary 3/17 (18%) 1—5% 1979 95
Hong Kong 5/15 (33%) 5—10% 1985 96
Hong Kong 10/23 (43%) 5—10% 1982 88
the vessel walls, suggesting that the localization of the HBsAg
was not due to non-specific trapping [71].
Although the deposition of CICs containing HBsAg appears
to be the most likely mechanism for HBV-PAN, other potential
mechanisms for HBV-PAN exist. HBV antigen containing ICs
could form in situ at the sites of injury in a mechanism similar
to that observed in many experimental glomerular diseases [78].
It is also possible that HBV infection induces autoantibodies
against endothelial or other antigens in the vessel wall as
apparently occurs in Kawasaki's vasculitis [73]. A cellular
immune response such as can be seen in mice with T cells
sensitized to vascular smooth muscle [79] has also not been
excluded. However, no evidence currently exists to implicate
these mechanisms in the HBV vasculitis syndromes, and CIC
deposition remains the most likely underlying pathogenetic
mechanism.
HBV associated membranous GN (HBV-MGN)
Association
HBV-MGN was first reported by Combes et al in 1971 [7]
who described a 53-year-old man who became a chronic HBsAg
carrier following an episode of symptomatic post-transfusion
hepatitis. One year later he presented with nephrotic syndrome
due to MGN in which HBsAg could be localized in the
glomerular capillary wall by IF [7]. The association of the
chronic "carrier" state of HBV with membranous nephropathy
is now well established, particularly in children, where the
frequency of the HBsAg carrier state in MGN correlates with
the underlying prevalence of HBsAg in the general population
(Table 4). In general, the frequency of HBsAg carriage in adult
patients with MGN is still significant but of a smaller magnitude
(Table 5).
Clinical presentation
Children with HBV-MGN typically present between the ages
of 2 and 12 (mean 6 yrs) with nephrotic syndrome or nonneph-
rotic proteinuria, and microscopic or rarely macroscopic hema-
tuna [81, 84, 90, 92, 97—99]. Hypertension is present in less than
25% of cases [90, 92], and only rarely do children with HBV-
MGN manifest renal insufficiency [80, 81, 91, 98]. Although
idiopathic MGN is associated with a slight male predominance
(ratio 1.4 [851), in HBV-MGN as many as 80 to 100% of children
are males [80, 81, 85, 86, 92, 98, 100, 101]. In the United States
a predominance in the black population has also been noted
[80].
Acquisition of the HBV virus in children appears to be
secondary to both vertical transmission from infected mothers
[97] and to horizontal transmission from infected siblings [90].
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Adults often have no known exposure, although individual
cases have been reported in patients with a history of intrave-
nous drug abuse [77], blood transfusion [7], homosexuality
[102—104], and acquired immune deficiency [102, 103].
Children with HBV-MGN generally have no history or clin-
ical evidence for ongoing liver disease [80], with rare exceptions
[105]. Adults with HBV-MGN are more likely than children to
have a history of acute hepatitis, usually six months to several
years prior to the onset of the kidney disease [7, 106]. Despite
a negative history for hepatitis, liver function tests, and espe-
cially transaminases, are usually mildly abnormal [80, 81, 85,
86, 92, 97, 98], in contrast to idiopathic MON [85]. The liver
pathology in children with HBV-MGN usually shows chronic
persistent hepatitis or minimal abnormalities [82—84, 90], but
rare cases have been reported in children with chronic active
hepatitis, cirrhosis, and even fulminant hepatitis [83, 84, 1071.
In contrast, the typical liver pathology in adults with HBV-
MON is chronic active hepatitis [104, 108], although cases have
been reported in patients with other forms of acute and chronic
HBV-induced liver disease [71, 102, 109—111]. Immune com-
plex deposits with early membranous and membranoprolifera-
tive changes have also been found in autopsy cases of 12 of 37
(32%) patients with acute and subacute HBV hepatitis and 16 of
18 (89%) patients with HBV chronic active hepatitis and cirrho-
sis despite the patients having had no clinical evidence of renal
disease [111].
Serology and immunopathology
HBsAg and anti-HBc can almost always be demonstrated in
the circulation [80, 85, 87, 90, 101, 102, 112]. Approximately 60
to 80% of patients with HBV-MGN will also have HBeAg and
the remainder will have anti-HBe antibody in their sera [85, 87,
97, 100, 101, 113]. Rare patients may be positive for both
HBeAg and anti-HBe [85, 92, 107, 114] or for both HBsAg and
anti-HBs [92, 115]. Examples also exist where HBsAg has been
found in the glomerulus of patients who lack HBsAg in their
sera[95, 110].
In most studies serum C3 and C4 levels have been depressed
in 15 to 64% of cases [80, 85, 87, 91, 100, 113], although in some
series complement levels are normal [81, 90, 97]. CICs have
been reported in up to 80% of cases of childhood HBV-MGN
[100, 101, 113], whereas CICs are only rarely found in idio-
pathic MGN [116]. In one study HBsAg immune complexes
were found in 55% and HBeAg immune complexes in 44% of
children with HBV-MGN [113].
In HBV-MGN IF staining of the glomerular capillary wall is
usually positive for IgG (100%), C3 (75%), 1gM (50%), and IgA
(10%) [80, 100], A distinguishing characteristic of HBV-MGN is
that the subepithelial immune deposits are frequently associ-
ated with subendothelial and/or mesangial deposits [80, 83,
85—87, 102, 103], in contrast to idiopathic MGN where deposits
are seen predominantly in a subepithelial location [85]. Occa-
sionally patients have an IgA or mesangial proliferative lesion
superimposed on a membranous GN [102, 117—119].
In HBV-MGN, viral-like particles have been identified by
EM in the subepithelial [77, 90, 120] and subendothelial [83]
areas of the GBM as well as within glomerular endothelial cells
[87], epithelial cells [71], and mesangium [77, 97, 119]. In many
of these studies the morphology and size of these particles is not
consistent with the 22 or 42 nm FEBV particles [87, 90, 97, 119],
but in at least one study the 42 nm HBV virion could be
identified by immuno-EM within mesangial cell lysosomes and
along the subendothelial and subepithelial aspect of the GBM
[110].
Pathogenesis of HBV-MGN
The pathogenic mechanism by which certain individuals with
chronic HBV infection develop MON is unknown. However,
all three major HBV antigens, including HBsAg [7, 71, 72, 77,
83, 84, 88, 90, 95, 100, 104—106, 108—hO, 113—115, 118, 119,
121], HBeAg [85, 86, 99—102, 112, 113, 122, 123] and HBcAg
[83, 84, 88, 118] have been localized by IF in the glomerular
capillary wall in HBV-MGN. This would support a mechanism
involving HBV antigen containing ICs, presumably localizing in
the subepithelial space either as a result of passive trapping of
CICs or due to local IC formation at this site [78, 124].
Alternatively, the presence of HBV antigens in the glomerulus
may be unrelated to the pathogenesis of HBV-MGN and the
HBV virus may cause the disease through other mechanisms,
such as an induction of autoantibodies to intrinsic glomerular
antigens. Finally, it remains possible that HBV and MGN may
both occur with increased frequency in a certain subset of
patients but be pathogenetically unrelated. Evidence for and
against each of these possibilities is discussed below.
Subepithelial immune deposit formation secondary to passive
trapping of CICs containing HBV antigens
CICs containing HBV antigens have been demonstrated in
many but not all patients with HBV-MGN [108, 112, 113].
However, CICs rarely result in subepithelial deposits unless the
CICs are very small and cationic [125]. HBsAg and HBcAg are
large (>106 daltons) and anionic (Table 2), and CICs containing
HBsAg have been identified in HBV-MGN with a molecular wt
of 2.5 to 3.6 x 106 daltons [113]. These are of a size that is
unlikely to penetrate the basement membrane into the subepi-
thelial space. In contrast HBeAg, which is also anionic, induces
anti-HBe antibodies that are largely cationic (isoelectric point
[p1] 5.8 to 10.2) [126] that can shift the p1 of HBeAg from 4.3 to
4.8 (that is, unbound) to the 6.4 to 8.4 range (that is, bound to
anti-HBe; Table 2) [13]. HBeAg CICs are also small (2.5 x 1O5
daltons) [113] and thus might be capable of localizing in the
subepithelial space [125]. HBeAg CICs have also been identi-
fied in 44% of children with HBV-MGN, and appear to correlate
with disease activity [113]. The potential importance of HBeAg
in HBV-MGN is further supported by the observations that
circulating HBeAg frequently correlates with the activity of the
disease [86, 92, 113], is the major antigen in the immune
deposits [85, 86, 99—101, 112, 113, 122, 123] and that those
biopsies negative for HBeAg occur very late in the disease
[123].
Thus, it is conceivable that the subepithelial deposits of
HBeAg and antibody could result from passive trapping of
small, cationic preformed CICs. However, there is currently
little experimental evidence to support a preformed CIC trap-
ping mechanism in the pathogenesis of MGN [78, 124], although
this mechanism might account for the mesangial and subendo-
thelial immune deposits seen frequently in HBV-MGN.
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Subepithelial immune deposits resulting from local IC
formation
In contrast to CIC trapping, local formation of antigen-
antibody complexes has been well established to induce the
diffuse subepithelial immune deposits and proteinuria charac-
teristic of HBV-MGN [1241. This process is usually initiated by
a charge interaction between a cationic antigen or antibody and
the highly anionic heparan sulfate proteoglycan present in the
glomerular capillary wall [1241. As discussed above, all three
major HBV antigens (HBsAg, HBcAg, and HBeAg) are an-
ionic, and only free HBeAg is of a size (molecular wt 3 to 9 x
iO daltons) that would be expected to penetrate the basement
membrane. However, as anti-HBe antibodies are cationic (p1
5.8 to 10.2) [126], sequential localization of cationic antibody
followed by anionic HBeAg could result in subepithelial IC
formation. This sequence has been shown experimentally to
induce typical subepithelial immune complex deposits when
cationic antibodies directed against various anionic antigens
were studied [127].
A local mechanism of deposit formation would be favored by
conditions which lead to persistence of free antigen or antibody
in the circulation, rather than large lattice IC formation that
results in rapid antigen elimination. In that regard, MGN
develops in a setting where antibody production is diminished
or antibody avidity is low—circumstances also characteristic of
idiopathic and lupus MGN [128, 129], of rabbits with MGN
secondary to chronic serum sickness [130, 1311, and of mice
that develop MGN following infection in utero with the lym-
phochoriomeningitis virus [132, 133]. The development of
MGN in patients with chronic HBsAg antigenemia suggests that
conditions which favor persistence of free antigen and antibody
may also prevail in these patients. Thus if HBV antigens are
pathogenic in HBV-MGN a local process of immune deposit
formation involving HBeAg and antibody would seem the most
likely mechanism.
Glomerular deposits of HBV antigens in HBV-MGN are not
pathogenic and the immune deposits develop by another viral
induced mechanism
The possibility that glomerular staining of HBV antigens may
be artifact is raised by the observation that many studies [8, 83,
115, 121] have not controlled for the presence of rheumatoid
factors within glomeruli that may bind anti-HBs and anti-HBe
antibodies non-specifically [134]. Also, studies in which HBsAg
is detected by indirect IF with anti-HBs followed by a fluores-
cein-labeled anti-IgG antibody must exclude potential cross-
reactivity of the anti-IgG antibody with human IgG present in
the lesion. Even when HBV antigens are unequivocally identi-
fied in glomeruli, their presence may represent non-specific
trapping of antigens in injured glomerular capillaries, as sug-
gested by the occasional observation of HBsAg in glomerular
diseases not believed to be due to immune complex deposition,
such as focal sclerosis [77] and minimal change disease [88,
100]. Non-specific trapping may also account for the glomerular
deposition of retroviral protein gp7O that can be frequently
demonstrated in murine lupus nephritis, as cross-hybrid studies
have demonstrated that immune complex ON can be induced in
mice in which glomerular deposition of gp7O was either not
detected or localized to areas of the glomerulus independent of
the immune complex deposits [135].
An alternative pathogenic mechanism for HBV-MGN could
involve the induction of autoantibodies to intrinsic glomerular
antigens. In passive Heymann nephritis, an experimental model
of MGN, GN is induced by an antibody directed against a
glomerular epithelial cell antigen [136]. Recent studies implicate
a similar mechanism involving autoantibodies directed against
intrinsic glomerular antigens in idiopathic MGN in man [124]. A
potential autoimmune etiology for HBV-MGN is further sup-
ported by the demonstration of autoantibodies in patients with
chronic HBV infection [137], including antibodies directed
against DNA [92, 138], cytoskeleton components [139], smooth
muscle [92, 137], liver membrane and liver-specific membrane
lipoprotein antigens [140, 141] and rat renal tubular brush
border [142]. Autoantibodies may contribute to some of the
liver injury in HBsAg-positive chronic active hepatitis [143].
The mechanism responsible for the induction of autoantibodies
in patients with chronic HBV infection is unknown. Viruses
may induce autoimmunity by a variety of mechanisms, includ-
ing cross reactions between viral and self antigens ("molecular
mimicry"), release of sequestered self antigens, alteration of
self antigens to induce an immune response, interference with T
cell tolerance, and generalized polyclonal B cell activation
[reviewed in 144]. Alternatively, chronic liver disease may
induce autoimmunity independently of HBV infection. Hyper-
gammaglobulinemia, a sign of polyclonal B cell activation, has
been observed in both HBsAg negative and HBsAg positive
patients with chronic active hepatitis [137]. Chronic active
hepatitis of other etiologies has also been associated with MGN
[145], especially in patients with autoimmune or "lupoid"
chronic active hepatitis [146, 147]. An autoantibody to glomer-
ular antigens has been identified in some patients with lupoid
chronic active hepatitis [148], including one patient with MGN
[case 10, ref 149]. Renal eluates from two patients with MGN
and lupoid hepatitis were concentrated 42- to 69-fold for anti-
Ul-RNP antibody, an autoantibody that is directed against a
small ribonucleoprotein [150]. Thus, given the autoimmune
nature of experimental and probably human idiopathic MGN,
and the presence of autoantibodies in chronic HBV infection,
an autoimmune etiology for HBV-MGN should not be ex-
cluded.
MGN and HBV infection are associated but are not
pathogenically related
Finally, the increased frequency of MGN in HBV infected
patients may not be caused by either HBV virus or secondary
liver disease, but rather may result from an underlying immu-
nologic abnormality or genetic predisposition that increases the
likelihood of these patients to develop both diseases indepen-
dently of each other. Conditions associated with defective
cell-mediated immunity do predispose HBV infected patients to
become chronic HBsAg carriers [143, 151, 152]. European
adults with chronic HBV infection but no obvious condition
associated with impaired immunity nevertheless can be shown
to have suboptimal in vitro interferon production [153]. Defects
in cell mediated immunity have also been reported in idiopathic
MGN [154, 1551, but it is not known whether these defects are
the consequence of the nephrotic syndrome or a predisposing
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factor for the development of the disease. Immunogenetic
studies have demonstrated an increased incidence of HLA B8
and DR3 in Europeans with idiopathic and drug-induced MGN,
and an increase in DR2 in the Japanese population [156—158].
Patients with lupoid chronic active hepatitis also have an
increased incidence of HLA B8 and DR3 [159], but these HLA
patterns are not typically seen in the chronic HBV carrier [159].
However, studies of the HLA patterns of patients with HBV-
MGN have not been reported. Thus, the possibility that MGN
and chronic HBV infection are not causally related but rather
are due to an inherent susceptibility of a subset of patients to
develop both diseases seems unlikely but has not been defini-
tively excluded.
HBV associated membranoproliferative (HBV-MPGN) and
mesangial proliferative GN
MPGN has also been reported in patients with chronic HBV
infection [8, 77, 84, 87, 95, 98, 100, 113, 121, 160—164]. Several
studies have reported that both adults [87] and children [97, 121]
with MPGN have a significantly higher carrier rate of HBsAg,
with the highest reported incidence of 66% in a study of children
from Poland (and 80% if HBV infection is measured using
circulating anti-HBc antibodies) [121] and 87.5% from a study
of adult patients from South Korea [87]. In contrast, a study
from Hong Kong could demonstrate no association of MPGN
with the HBsAg carrier state [96].
Patients commonly manifest nephrotic syndrome and micro-
hematuria. In one series hypertension was reported in 45% of
patients and renal insufficiency in 20% [87]. HBsAg and anti-
HBc are usually present in the serum [121, 161], but two
patients have been described who were HBsAg negative and
anti-HBc positive in the circulation yet had MPGN with HBsAg
deposits in their glomeruli [121]. As in HBV-MGN, patients
frequently have no history of clinical hepatitis despite having
abnormal liver function tests (that is, transaminases) on presen-
tation [87]. Liver histology usually shows chronic active or
chronic persistent hepatitis [8, 87, 162], and rarely cirrhosis
[871, but mild MPGN has been described in autopsy cases of
patients with acute fulminant hepatitis [ill]. Serum comple-
ment levels (C3, C4) are often depressed [8, 87], and CICs may
be present [98].
The renal lesion is histologically similar to MPGN I, with
pronounced subendothelial deposits and mild proliferation
[160]. The pathology may also resemble MPGN III, in which
there are also coexistent small subepithelial and mesangial
deposits [86, 87, 161, 163]. In many cases HBsAg has been
localized by IF to the glomerular capillary wall [8, 48, 86,95, 98,
121, 160—163], and in one case of MPGN III, HBeAg was also
present in a capillary wall distribution [1631.
Mesangial proliferative GN, in which an increase in mesan-
gial cell cellularity and matrix occurs in conjunction with the
deposition of IgG and/or 1gM, has also been observed in HBV
carriers [84, 92, 95, 111, 165] at a greater frequency than
expected for the underlying prevalence of the HBsAg carrier
rate [88]. Mild mesangial proliferation and/or expansion has
also been described during acute hepatitis B infection in man
[1661 and has been reported in HBV infected baboons 4 to 10
months following inoculation [167]. In the lesions in chronic
HBV infected patients, HBsAg [48, 88, 95, 165, 168] and
HBcAg [88, 168] have been localized by IF to the mesangium.
In one case with membranous changes HBeAg [102] was also
localized to the capillary wall.
The pathogenesis of both HBV-MPGN and HBV mesangial
proliferative GN most likely involves mesangial and subendo-
thelial trapping of CICs by a mechanism similar to that de-
scribed above in the section on HBV vasculitis. The observa-
tion that infusion of preformed CICs primarily results in
subendothelial and mesangial deposits would support this
mechanism [169]. In one case of mild MPGN HBsAg could be
identified in glomeruli, anti-HBs antibody was eluted from the
renal tissue, and CICs were shown to contain HBsAg and
anti-HBs antibody [164]. It is also possible that some of the
mesangial proliferation in these lesions may relate to direct
infection of the mesangial cell by the HBV virus. The HBV
virus is capable of infecting other cells besides the hepatocyte,
including pancreatic acinar cells, monocytes, and perhaps other
bone marrow-derived cells [170, 171]. Evidence also exists that
the related hepadna virus, the Pekin duck hepatitis B virus, can
infect kidney cells [172], possibly including glomeruli [173]. The
demonstration by immunoperoxidase of HBcAg within the
nuclei of mesangial cells in patients with HBV-IgA disease [117,
168] is highly suggestive of HBV infection of the mesangial cell,
given the recognition that intranuclear HBcAg in hepatocytes is
evidence of active infection [174]. Furthermore, in one patient
with HBV-MPGN, complete HBV virions, as stained by immu-
noperoxidase EM, were noted in mesangial cell cytoplasm and
matrix and appeared to be "budding" from the cell membranes
[77]. Finally, the recent demonstration by in situ hybridization
of the HBV viral DNA within the mesangium in two patients
with IgA disease [117] and the identification of both free and
integrated HBV DNA in kidneys of patients with chronic HBV
infection, including a patient with HBV-MGN, provides evi-
dence that the HBV virus may also infect resident glomerular
cells [171].
Other types of GN reported in HBV infected patients
Several other types of GN have been reported with HBV
infection but the association remains controversial. In chronic
liver disease of any etiology increased mesangial deposits of
IgA can occur resulting in lesions similar to that observed in
IgA nephropathy and Henoch-SchOnlein purpura (HSP) [145,
175, 176]. Thus it is not surprising that IgA containing CICs
[177], IgA nephropathy [88, 117, 168] and HSP [95, 178] have
also been reported in chronic HBV infected patients. In some
cases mesangial deposits of HBsAg and/or HBcAg have also
been demonstrated [88, 95, 117, 168, 179].
Chronic liver disease due to HBV may also be associated
with mixed cryoglobulinemia and an immune complex nephritis
[180—183]. Although one study demonstrated that the cryoglob-
ulins contained HBsAg and/or antibodies [180], mixed cryo-
globulins and GN have been observed with chronic liver disease
of other etiologies [145].
Patients with systemic lupus erythematosus (SLE) have also
been reported to have an increased frequency of HBsAg
antigenemia [184, 185] and to have glomerular immune deposits
containing HBsAg and/or HBcAg [186]. However, others have
not been able to localize HBV antigens in glomeruli of patients
with SLE [7, 83], and false positive IF results are possible if
careful attempts are not made to exclude rheumatoid factors
670 Johnson and Couser; Hepatitis B virus
[134] in glomeruli that can bind anti-HBV antibodies non-
specifically. The increased incidence of HBsAg antigenemia in
patients with SLE has also not been consistently observed [29,
86. 88, 188], and when present may be partially explained by the
observation that antibodies to both single stranded and double
stranded DNA may occur in patients with chronic HBV liver
disease [138], and by the theoretical possibility that immuno-
suppressive therapy used in the treatment of SLE may predis-
pose patients who are infected with HBV to necome chronic
carriers 1151]. This latter mechanism may also account for the
increased frequency of HBsAg antigenemia observed in a study
of Italian children with minimal change disease [82]. Most
studies, however, have not noted an associated of minimal
change disease with chronic HBV infection [81, 83, 88, 91, 96].
Other types of GN rarely reported in HBV infected patients
include diffuse [22, 39, 40, 121, 189] proliferative GN, and
crescentic GN [48, 55, 121, 179], particularly in patients with
HBV-vasculitis [22, 40, 48]. Idiopathic crescentic GN with or
without segmental necrosis and without systemic manifesta-
tions is not usually associated with HBV infection [56]. One
case of focal sclerosis in which the HBsAg was localized to the
sclerotic regions of the glomerulus has also been reported [77].
Recently, an outbreak of acute fulminant HBV infection was
reported in which several patients developed acute GN [190].
However, no histology was reported in these patients.
Treatment of IIBV-related syndromes
General considerations
Immunosuppressive therapy, although useful in treating var-
ious forms of GN and vasculitis, may retard the ability of the
host to eradicate HBV infection [151]. Normally, HBV infec-
tion results in a cell mediated response in which cytotoxic T and
natural killer cells eliminate infected hepatocytes expressing
HBcAg on their cell surface [191]. An ineffectual cell-mediated
response to HBV results in the development of the chronic
carrier state [151]. Thus, patients with defective cell-mediated
immulliLy, such as patients with uremia, chronic lymphatic
leukemia, and Down's syndrome, have a high HBV carrier rate
[152, 192]. European adult HBV carriers also have defects in
cell mediated immunity, particularly in their ability to produce
optimal amounts of interferon [153]. The increased incidence of
the HBV carrier state in the neonate is not entirely explained,
but may relate to insufficient gamma interferon production [193]
or the maternal transfer of anti-HBc blocking antibodies [143,
191].
Given the importance of cell mediated immunity in the
elimination of the HBV virus, it is not surprising that the
administration of steroids is of no benefit in acute hepatitis B
[194] and may increase the risk of progressing to chronic active
hepatitis [195]. Prolonged steroid treatment in chronic active
hepatitis secondary to HBV infection is associated with de-
creased survival [196], and short course steroid therapy fol-
lowed by withdrawal is of no benefit and may worsen the
histologic lesion [197]. Steroid and/or cytotoxic therapy also
results in enhanced HBV viral replication [198, 199], and can
occasionally lead to re-emergence of HBsAg in patients previ-
ously anti-HBs positive [199]. If the cell-mediated immune
response is completely inhibited, the increase in HBV viral
replication is clinically silent [151]. However, sudden cessation
of immunosuppression may lead to a reconstitution of cell
mediated immunity [191] and fulminant hepatitis may result
[200]. If immunosuppression only partially inhibits the cell
mediated response, the enhanced HBV viral replication may
result in progressive liver disease, and this appears to be a
frequent pattern in HBV infected renal transplant patients
[201].
Treatment of JiB V-PAN
In untreated idiopathic PAN the mortality rate is high (sur-
vival at 1 year 42%; 5 years 12% [202, 2031), and most studies
suggest that the prognosis is substantially improved by treat-
ment with steroids and cytotoxic drugs [30, 33, 202, 203]. No
study has specifically addressed the treatment of HBV-PAN.
Uncontrolled studies in small numbers of patients have sug-
gested that steroids and/or cytotoxic therapy may be of benefit
[33, 43, 45, 46, 68, 204]. In the series reported by Sergent et al,
three of nine patients with HBV-PAN died five to seven months
after onset of the disease secondary to active vasculitis com-
plicated by chronic active hepatitis [43]. Of the six patients that
responded favorably in the short term (6 mos) to steroid and/or
cytotoxic therapy, two aeveloped chronic active hepatitis (one
dying of this complication at 84 months) and two developed
hypertension with azotemia in one [43]. Immunosuppressive
therapy was gradually weaned in four of the five surviving
patients, and relapses were not observed [21, 43].
In the rare patient who clears the HBsAg and develops
anti-HBs antibodies dramatic remission has been documented
[37]. However, most patients with HBV-PAN are treated with
immunosuppressive therapy and continue to be HBsAg positive
in their serum. Thus, it is likely that the use of steroids and/or
other immunosuppressive agents may be required to control the
vasculitis, but at the expense of maintaining the carrier state
and potentially predisposing the patient to progressive liver
disease. At this time, however, steroids with or without cyto-
toxic agents remain the standard treatment regimen. Other
treatments, such as dapsone, or plasmapheresis, the latter
which can both remove CICs and improve clearance of CICs by
the spleen [205], have been used successfully in HBV-PAN in
only individual cases [206, 207]. Therapies directed against the
HBV virus itself (that is, interferon, adenine arabinoside) have
not to our knowledge been reported in HBV-PAN.
Treatment of HBV-MGN and other types of HBV-GN
Although several controlled studies of adults with idiopathic
MGN suggest a benefit from steroid and/or cytotoxic therapy
[208—2101, children with idiopathic MGN generally have a good
prognosis and can be supported conservatively [211]. No con-
trolled studies of steroid treatment in HBV-MGN have been
reported. However, uncontrolled studies suggest that children
with HBV-MGN have similar spontaneous remission rates as
childrcn with idiopathic MGN [81, 851. In one study two-thirds
of children with HBV-MGN were in remission three years after
diagnosis [921. Steroid therapy does not appear to provide any
additional benefit [81, 84, 91]. However, in one case withdrawal
of steroid therapy resulted in an immunologic rebound with
remission of the nephrotic syndrome and clearing of the
HBeAg, and later, of the HBsAg [107].
Small numbers of patients with HBV-MGN have been treated
with alpha interferon [114, 212—214] and adenine arabinoside
monophosphate [215] in an effort to eradicate the HBV virus.
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This is based on the observation that clearance of HBeAg [113,
123], even in the absence of clearing HBsAg [81, 921 is
frequently associated with resolution of the nephrotic syn-
drome. In six patients treated with alpha interferon, suppres-
sion of HBV expression with clearance of the HBeAg resulted
in either a complete or partial remission [212—214], Two other
patients, however, had only a transient complete and partial
remission to an initial course of therapy, and in one patient the
nephrotic syndrome returned despite being both HBsAg and
HBeAg negative [114]. In the single case treated with a short
course of steroids followed by a six week course of adenine
arabinoside monophosphate complete eradication of the virus
with clearing of both HBeAg and HBsAg and remission of the
renal disease was achieved [2151. The use of adenine arabino-
side monophosphate, however, may be limited due to its
potential ability to cause painful neuropathies [216].
These hopeful results will obviously require additional study
and confirmation. However, as noted earlier, it is not clear that
eradication of the HBV virus is required to induce remission of
the HBV-MGN. Thus, persistent proteinuria may be associated
with anti-ilBe [80, 92] or anti-HBs [92] antibodies, and remis-
sion may occur despite remaining HBeAg [85, 92] or HBsAg
[81, 92] positive.
No studies have addressed the treatment of other types of
HBV-GN. Both alpha interferon (214, A.M. DiBisceglie, per-
sonal communication) and beta interferon (H. lida, personal
communication) have been used to treat two patients each with
HBV-MPGN. However, only one of the patients treated with
beta interferon had a significant decrease in proteinuria. As
renal failure requiring dialysis has only rarely been reported in
patients with HBV-GN [81, 91, 98, 117], it would seem reason-
able to manage patients conservatively until further experience
with these therapies are obtained.
Conclusion
Considerable world-wide experience over the past 25 years
has demonstrated that infection with HBV is associated with
several immunologic syndromes, including a serum sickness-
like syndrome that is seen with acute infection, and polyarteritis
nodosa, membranous GN, and membranoproliferative GN that
are seen primarily in patients with chronic HBV infection. The
pathogenesis of the serum sickness/vasculitis syndromes and
HBV-MPGN most likely involve deposition of circulating im-
mune complexes containing HBV antigens. In contrast, in
HBV-MGN in situ immune complex formation or the induction
of autoantibodies to intrinsic glomerular antigens may be more
likely to underlie the pathogenesis. Steroids and cytotoxic
agents remain the mainstay of treatment of HBV-PAN, but may
have potentially serious long-term consequences. In contrast,
therapy for most types of HBV-GN should be supportive only.
The role of antiviral therapy in the management of these
syndromes has yet to be defined.
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Note added in proof
A potential role for HBeAG in HBV-MN has been further
supported by the recent demonstration of anti-HBe antibodies
in renal biopsy tissue eluates from three children with HBV-
MN [217]:
217. HATFORI S, FURUSE A, MATSUDA I: Presence of HBe antibody in
glomerular deposits in membranous glomerulonephritis is associ-
ated with Hepatitis B virus infection. Am J Nephrol 8:384—387,
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